Neurotech International Croissance future

Future contrôle des critères 2/6

Neurotech International devrait augmenter ses bénéfices et son chiffre d'affaires de 33.6% et de 44.7% par an respectivement. Le BPA devrait croître de diminuer de 90.1% par an. Le rendement des capitaux propres devrait être -45% dans 3 ans.

Informations clés

33.6%

Taux de croissance des bénéfices

-90.1%

Taux de croissance du BPA

Medical Equipment croissance des bénéfices	16.2%
Taux de croissance des recettes	44.7%
Rendement futur des capitaux propres	-45.0%
Couverture par les analystes	Low
Dernière mise à jour	16 Aug 2024

Mises à jour récentes de la croissance future

Pas de mise à jour

Recent updates

Why Neurotech International Limited (ASX:NTI) Could Be Worth Watching

Nov 19

Neurotech International (ASX:NTI) Is In A Good Position To Deliver On Growth Plans

Sep 19

Here's Why We're Watching Neurotech International's (ASX:NTI) Cash Burn Situation

Jan 28

We Think Neurotech International (ASX:NTI) Needs To Drive Business Growth Carefully

Oct 14

Here's Why We're Not Too Worried About Neurotech International's (ASX:NTI) Cash Burn Situation

Jul 01

Is Neurotech International (ASX:NTI) In A Good Position To Invest In Growth?

Jan 21

Is Neurotech International (ASX:NTI) In A Good Position To Deliver On Growth Plans?

Oct 06

Here's Why We're Watching Neurotech International's (ASX:NTI) Cash Burn Situation

May 18

We're Not Very Worried About Neurotech International's (ASX:NTI) Cash Burn Rate

Dec 21

Neurotech International (ASX:NTI) Is In A Good Position To Deliver On Growth Plans

Sep 04

Need To Know: Neurotech International Limited (ASX:NTI) Insiders Have Been Selling Shares

Dec 08

Prévisions de croissance des bénéfices et des revenus

ASX:NTI - Estimations futures des analystes et données financières antérieures (AUD Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
6/30/2027	3	-7	-8	-8	1
6/30/2026	3	-6	-6	-6	1
6/30/2025	2	-6	-6	-6	1
6/30/2024	3	-5	-5	-5	N/A
3/31/2024	3	-5	-4	-4	N/A
12/31/2023	3	-5	-4	-4	N/A
9/30/2023	2	-6	-5	-5	N/A
6/30/2023	1	-8	-6	-6	N/A
3/31/2023	1	-6	-5	-5	N/A
12/31/2022	2	-5	-4	-4	N/A
9/30/2022	1	-4	-4	-4	N/A
6/30/2022	1	-3	-3	-3	N/A
3/31/2022	0	-4	-3	-3	N/A
12/31/2021	0	-6	-3	-3	N/A
9/30/2021	0	-7	-3	-3	N/A
6/30/2021	0	-7	-2	-2	N/A
3/31/2021	0	-6	-2	-2	N/A
12/31/2020	0	-5	-1	-1	N/A
9/30/2020	0	-3	-1	-1	N/A
6/30/2020	0	-2	-1	-1	N/A
3/31/2020	0	-3	-1	-1	N/A
12/31/2019	0	-4	-1	-1	N/A
9/30/2019	0	-4	-2	-2	N/A
6/30/2019	0	-5	-3	-3	N/A
3/31/2019	0	-4	-3	-3	N/A
12/31/2018	0	-4	-4	-3	N/A
9/30/2018	0	-4	-4	-3	N/A
6/30/2018	0	-4	-4	-3	N/A
3/31/2018	0	-4	N/A	-3	N/A
12/31/2017	0	-4	N/A	-3	N/A
9/30/2017	0	-4	N/A	-3	N/A
6/30/2017	0	-4	N/A	-3	N/A
12/31/2016	0	-4	N/A	-3	N/A
9/30/2016	0	-4	N/A	-2	N/A
6/30/2016	0	-3	N/A	-2	N/A
12/31/2015	0	-1	N/A	-1	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: NTI devrait rester non rentable au cours des 3 prochaines années.

Bénéfices vs marché: NTI devrait rester non rentable au cours des 3 prochaines années.

Croissance élevée des bénéfices: NTI devrait rester non rentable au cours des 3 prochaines années.

Chiffre d'affaires vs marché: Le chiffre d'affaires de NTI ( 44.7% par an) devrait croître plus rapidement que le marché Australian ( 5.8% par an).

Croissance élevée des revenus: Le chiffre d'affaires de NTI ( 44.7% par an) devrait croître plus rapidement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: NTI devrait être non rentable dans 3 ans.

Neurotech International Croissance future

Future contrôle des critères 2/6

Informations clés

Mises à jour récentes de la croissance future

Recent updates

Why Neurotech International Limited (ASX:NTI) Could Be Worth Watching

Now 21% overvalued

Now 20% overvalued

Neurotech International Limited, Annual General Meeting, Nov 20, 2024

Neurotech International (ASX:NTI) Is In A Good Position To Deliver On Growth Plans

Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Less than half of directors are independent

Neurotech International Limited has completed a Follow-on Equity Offering in the amount of AUD 10 million.

Neurotech International Limited has completed a Follow-on Equity Offering in the amount of AUD 10 million.

Here's Why We're Watching Neurotech International's (ASX:NTI) Cash Burn Situation

Independent Non-Executive Director exercised options to buy AU$114k worth of stock.

Neurotech International Limited to Report Q1, 2024 Results on Oct 27, 2023

Neurotech International Limited, Annual General Meeting, Nov 15, 2023

We Think Neurotech International (ASX:NTI) Needs To Drive Business Growth Carefully

Full year 2023 earnings released: AU$0.01 loss per share (vs AU$0.005 loss in FY 2022)

New minor risk - Financial data availability

Neurotech International Limited to Report Q4, 2023 Results on Jul 26, 2023

New minor risk - Share price stability

Here's Why We're Not Too Worried About Neurotech International's (ASX:NTI) Cash Burn Situation

First half 2023 earnings released: AU$0.48 loss per share (vs AU$0.003 loss in 1H 2022)

Neurotech International Limited Announces First Patient Treated in Phase I/II PANDAS/PANS Trial

Neurotech International Limited Announces Approval for Additional Phase I/II ASD Trial Extension

Neurotech International Limited Receives HREC Approval for Phase I/II PANDAS/PANS Clinical Trial

Neurotech International Limited to Report Q3, 2023 Results on Jan 30, 2023

Is Neurotech International (ASX:NTI) In A Good Position To Invest In Growth?

Neurotech International Limited Announces Grant of FDA Pre-IND Meeting for NTI164 in ASD

Neurotech International Limited Announces Passing of Professor Allan Cripps AO, Non-Executive Director

Neurotech International Limited Announces Commencement of Patient Randomisation and First Patient Successfully Treats Under New Phase II/III NTIASD2 Clinical Trial for Children with Autism Spectrum Disorder

Less than half of directors are independent

Neurotech International Limited, Annual General Meeting, Nov 30, 2022

Neurotech International Limited, Annual General Meeting, Nov 23, 2022

Neurotech International Limited Reports Further Significant Clinical Improvement at 20 Weeks for Paediatric Autism Patients Treated with NTI164

Neurotech International Limited Announces New Phase I/II Clinical Trial in Children with PANDAS/PANS

Is Neurotech International (ASX:NTI) In A Good Position To Deliver On Growth Plans?

Neurotech International Limited Provides Autism Spectrum Disorder Phase I/II Clinical Trial Update

Less than half of directors are independent

Neurotech International Limited Announces Transition of Alexandra Andrews from Chief Executive Officer to a New Position of Chief Operating Officer

Full year 2022 earnings released: AU$0.005 loss per share (vs AU$0.015 loss in FY 2021)

Neurotech International Limited Announces Currently Finalising a Pivotal Phase II/III Clinical Trial Design to be Conducted in Australia

Neurotech International ORDINARY FULLY PAID to Be Deleted from OTC Equity

Neurotech International Limited Announces Executive Changes

Neurotech International Limited Announces Results with NTI164 in Paediatric ASD

High number of new directors

Here's Why We're Watching Neurotech International's (ASX:NTI) Cash Burn Situation

Neurotech International Limited Announces Important Developments Relating to the Study Protocol Assessing NTI164 in Children with Autism Spectrum Disorder

High number of new directors

Neurotech International Limited Announces Successful Developments Relating to Safety and Tolerability of NTI164 and Key Behavioural Parameters That Impact Autism Spectrum Disorder Patients

Neurotech International Limited Appoints Alexandra Andrews as Chief Executive Officer, Effective 8 March 2022

We're Not Very Worried About Neurotech International's (ASX:NTI) Cash Burn Rate

Neurotech International Limited Announces Nti164 Clinical Program Update

Neurotech International (ASX:NTI) Is In A Good Position To Deliver On Growth Plans

Full year 2021 earnings released: AU$0.015 loss per share (vs AU$0.011 loss in FY 2020)

Neurotech International Limited Announces the Continuation of Its Pre-Clinical Program in Neuro-Inflammatory Disease Models In-Line with Research and Development Pathway

Neurotech International Limited Initiates Phase I/II Open Label Study into Autism

Neurotech International Limited has completed a Follow-on Equity Offering in the amount of AUD 2 million.

Neurotech International Limited Announces Strategic Cultivation Partnership with CannaPacific Limited

Neurotech International Limited Announces the Expansion of Its Exclusive License with Dolce Cann Global Pty Ltd

Neurotech International Limited Provides an Update on Clinical Study Program

Neurotech International Limited has completed a Follow-on Equity Offering in the amount of AUD 2.5 million.

Need To Know: Neurotech International Limited (ASX:NTI) Insiders Have Been Selling Shares

Neurotech International Limited Announces Initiation of Clinical Product Formulation Studies

Neurotech International Limited Announces Transition of Peter Griffiths as CEO

Neurotech International Limited Commences Landmark in Vitro Trials of Unique Cannabis Strains

Full year earnings released - AU$0.011 loss per share

Prévisions de croissance des bénéfices et des revenus

Prévisions de croissance des analystes

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

Découvrir les entreprises en croissance